The mention of recent or upcoming purchases of a computer and a car suggests strong consumer demand. Your plan to refinance your home is a positive sign for the future, implying that you are confident in your ability to meet future mortgage payments. The refinancing suggests also the possibility of lower mortgage payments, which could mean an increase in your discretionary income. Your neighbor's promotion and the start of his wife's new business are also positive economic signs. The only negative reference during the conversation was the mention of one person who recently lost a job. But from the other information exchanged between you and your neighbor, the economist might conclude that consumer confidence is high. That is good news for the economy because, on average, consumers are responsible for two-thirds of the nation's economic activity, or the gross domestic product (GDP).
Top 5 Biotech Stocks To Watch Right Now: Books-A-Million Inc.(BAMM)
Books-A-Million, Inc. operates as a book retailer in the southeastern United States. The company operates superstores and traditional bookstores that offer a selection of hardcover and paperback books, magazines, and newspapers. It also offers other merchandise, including gifts, cards, collectibles, magazines, music, DVDs, and electronic accessories, as well as coffee, tea, and other edible products. The company markets its products under the trademarks of Books-A-Million, BAM! Books-A-Million, Bookland, Books & Co., Millionaire?s Club, Sweet Water Press, Thanks-A-Million, Big Fat Coloring Book, Up All Night Reader, Read & Save Rebate, Readables Accessories for Readers, Kids-A-Million, Teachers First, The Write-Price, Bambeanos, Hold That Thought, Book$mart, BAMM, BAMM.com, BOOKSAMILLION.com, Chillatte, Joe Muggs Newsstand, Page Pets, JOEMUGGS.com, FAITHPOINT.com, Faithmark, Joe Muggs, Anderson?s Bookland, Snow Joe, Summer Says, On the John University, OTJU, American Whole sale Book Company, AWBC, and NetCentral. It also offers its products over the Internet at Booksamillion.com. As of August 11, 2011, the company operated 231 stores in 23 states and the District of Columbia. Books-A-Million, Inc. was founded in 1917 and is based in Birmingham, Alabama.
Advisors' Opinion:- [By Peter Graham]
Mid�cap video game retailer stock GameStop Corp (NYSE: GME), who�� potential peers may include small caps Books-A-Million, Inc (NASDAQ: BAMM) and Trans World Entertainment Corporation (NASDAQ: TWMC), is ranked as the sixth most shorted stock on the NYSE with short interest of 42.02% according to Highshortinterest.com. However, there�� good reason for the high short interest and many shorts and investors alike feel that GameStop Corp�� brick and mortar strategy to sell games is very old school as retail increasingly shifts online.
- [By John Udovich]
Vitamin Shoppe Inc (NYSE: VSI), Books-A-Million, Inc (NASDAQ: BAMM) and Perfumania Holdings, Inc (NASDAQ: PERF) have the dubious distinction of being�the worst performing small cap�specialty retail stocks for this year (according to Finviz.com) with losses of 4.85% and�3% and a gain of 0.61%, respectively, since the start of the year (See my previous article: This Year�� Best Performing Small Cap Specialty Retail Stocks? UNTD, TA & HZO). I should mention that the definition of specialty retail stocks might vary from one stock screener to another, but what�� clear is that these three small cap retail stocks have been heading in the wrong direction for investors for much of this year. �With that in mind, what sort of performance should investors expect from these small cap specialty retail stocks on Black Friday and for the all important holiday season? Here is what you need to be aware of:
Top 5 Forestry Companies To Buy For 2014: Symmetry Medical Inc (SMA)
Symmetry Medical Inc. designs, develops, and produces implants and related surgical instruments and cases to orthopedic device manufacturers worldwide. It offers orthopedic implants that are used in reconstructive surgeries to replace or repair hips, knees, and other joints, such as shoulders, ankles, and elbows; trauma implant systems, which are used primarily to reattach or stabilize damaged bone or tissue while the body heals; and spinal implant systems, including plates and screws used by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities, and injuries in various regions of the spine. The company also provides surgical instruments, such as knee cutting blocks, osteotome revision systems, reamers, and retractors used in hip, knee, and shoulder reconstruction procedures, as well as in spinal, trauma, and other implant procedures. In addition, it produces a range of plastic, metal, and hybrid orthopedic cases to store, transport, and arrange surgical instruments and related implant systems, and other medical devices for orthopedic device manufacturers; endoscopy cases for endoscope sterilization; dental cases used in dental implant and general dental procedures; sterilization containers for the sterilization of various surgical instruments; and other cases for arthroscopy, osteobiologic, cardiovascular, ophthalmology, and diagnostic imaging, as well as ear, nose, and throat procedures. Further, the company engages in the design, engineering, and manufacturing of aerospace products comprising net shaped aerofoils and non-rotating aircraft engine forgings produced for the aerospace customers; and offers aerospace machining capabilities. The company was founded in 1976 and is headquartered in Warsaw, Indiana.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Symmetry Medical (NYSE: SMA ) , a medical device solutions and surgical instruments manufacturer, dipped as much as 17% after the company updated its second-quarter and full-year financial guidance.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Symmetry Medical (NYSE: SMA ) , whose recent revenue and earnings are plotted below. - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Symmetry Medical (NYSE: SMA ) , whose recent revenue and earnings are plotted below. - [By Roberto Pedone]
One under-$10 health care player that's starting to trend within range of triggering a near-term breakout trade is Symmetry Medical (SMA), which designs, develops and produces medical device solutions and surgical instruments. This stock has been hit by the sellers in 2013, with shares off by 22%.
If you take a look at the chart for Symmetry Medical, you'll notice that this stock has been finding some buying interest over the last two months, each time it's pulled back to around $7.75 a share. That action has started to form a bottoming pattern for SMA near that $7.75 level. Shares of SMA are now starting to challenge its 50-day moving average of $8.20 a share. That move is quickly pushing shares of SMA within range of triggering a near-term breakout trade.
Traders should now look for long-biased trades in SMA if it manages to break out above some near-term overhead resistance levels at $8.29 to $8.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 129,189 shares. If that breakout hits soon, then SMA will set up to re-test or possibly take out its next major overhead resistance levels at $9.40 to its 200-day moving average of $9.59 a share. Any high-volume move above those levels will then put $10.50 to $11 into range for shares of SMA.
Traders can look to buy SMA off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $7.75 a share, or at $7.44 a share. One can also buy SMA off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 5 Forestry Companies To Buy For 2014: Titan Pharmaceuticals Inc (TTNP.OB)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-ter m drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ! i! loperidone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated wit h human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide deve lopment, manufacturing and commercialization rights, an! d, in! ad! dition! to the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By C.R. Jackson]
Fanapt was discovered by Hoechst Marion Roussel in 1995 as a novel atypical antipsychotic agent. Hoechst was a German life-sciences company that became Aventis Deutschland after its merger with France's Rhône-Poulenc in 1999. When the company joined with Sanofi-Synthélabo in 2004, it became a subsidiary of the Sanofi-Aventis (SNY) the French pharmaceutical conglomerate. In 1997, Hoechst sold the research rights to Titan Pharmaceuticals (TTNP.OB). Then Titan quickly sold the worldwide rights to Novartis in 1998. Novartis then sold the Phase 3 development rights for loperidone to Vanda in 2004. Vanda originally attempted to get FDA approval for Fanapt in 2008, but the FDA refused to approve iloperidone. The agency required an additional clinical trial.
Top 5 Forestry Companies To Buy For 2014: Network Engines Inc(NEI)
Network Engines, Inc. designs and manufactures application platforms and appliance solutions on which software applications are applied for enterprise and telephony information technology networks. The company?s application platforms are pre-configured server-based network infrastructure devices designed to deliver specific software application functionality, and enhance the integration, manageability, and security of that software application in an end user?s network. It also offers platform management software tools and support services related to solution design, systems integration, application management, global logistics, and support and maintenance programs. The company markets its application platform solutions and services to original equipment manufacturers and independent software vendors in the United States and internationally. Network Engines, Inc. was founded in 1989 and is headquartered in Canton, Massachusetts.
Advisors' Opinion:- [By CRWE]
NEI (Nasdaq:NEI), a leading provider of server-based application platforms, deployment solutions and lifecycle support services for software technology developers and OEMs worldwide, announced today that it has signed a definitive merger agreement with UNICOM Systems, Inc. (“UNICOM”) and a new UNICOM subsidiary under which UNICOM, a global information technology company and part of the UNICOM group of companies, will acquire NEI for $1.45 per common share in cash.
No comments:
Post a Comment